Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the In Vitro Potency of Direct-Acting Antiviral Agents.

McPhee F, Ueland J, Vellucci V, Bowden S, Sievert W, Zhou N.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02205-18. doi: 10.1128/AAC.02205-18. Print 2019 Apr.

PMID:
30718256
2.

Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.

McPhee F, Hernandez D, Zhou N, Ueland J, Yu F, Vellucci V, Huang X, Wang X, Ishikawa H, Karino Y, Kumada H.

Antivir Ther. 2018;23(1):53-66. doi: 10.3851/IMP3177.

PMID:
28594332
3.

Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.

Zhou N, Han Z, Hartman-Neumann S, DeGray B, Ueland J, Vellucci V, Hernandez D, McPhee F.

J Antimicrob Chemother. 2016 Dec;71(12):3495-3505. Epub 2016 Sep 7.

PMID:
27605597
4.

NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.

Zhou N, Hernandez D, Ueland J, Yang X, Yu F, Sims K, Yin PD, McPhee F.

J Infect Dis. 2016 Jan 15;213(2):206-15. doi: 10.1093/infdis/jiv379. Epub 2015 Jul 13.

5.

Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.

McPhee F, Hernandez D, Zhou N, Yu F, Ueland J, Monikowski A, Chayama K, Toyota J, Izumi N, Yokosuka O, Kawada N, Osaki Y, Hughes EA, Watanabe H, Ishikawa H, Kumada H.

Antivir Ther. 2014;19(5):479-90. doi: 10.3851/IMP2729. Epub 2014 Jan 22.

PMID:
24448487
6.

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.

McPhee F, Hernandez D, Yu F, Ueland J, Monikowski A, Carifa A, Falk P, Wang C, Fridell R, Eley T, Zhou N, Gardiner D.

Hepatology. 2013 Sep;58(3):902-11. doi: 10.1002/hep.26388. Epub 2013 Jul 16.

PMID:
23504694
7.

Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors.

Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F.

J Clin Virol. 2013 May;57(1):13-8. doi: 10.1016/j.jcv.2012.12.020. Epub 2013 Feb 4. Erratum in: J Clin Virol. 2016 Apr;77:115.

PMID:
23384816
8.

A novel role for the chemokine receptor Cxcr4 in kidney morphogenesis: an in vitro study.

Ueland J, Yuan A, Marlier A, Gallagher AR, Karihaloo A.

Dev Dyn. 2009 May;238(5):1083-91. doi: 10.1002/dvdy.21943.

9.

Global Impact of Recreational Fisheries.

Arlinghaus R, Cooke SJ, Coleman FC, Figueira WF, Ueland JS, Crowder LB.

Science. 2005 Mar 11;307(5715):1561-1563. No abstract available.

PMID:
15764588
10.

The Recreational Fisher's Perspective.

Nussman M, Coleman FC, Figueira WF, Ueland JS, Crowder LB.

Science. 2005 Mar 11;307(5715):1560c-1561c. No abstract available.

PMID:
15764587
11.

Expression of neutrophil gelatinase-associated lipocalin regulates epithelial morphogenesis in vitro.

Gwira JA, Wei F, Ishibe S, Ueland JM, Barasch J, Cantley LG.

J Biol Chem. 2005 Mar 4;280(9):7875-82. Epub 2005 Jan 6.

12.

The impact of United States recreational fisheries on marine fish populations.

Coleman FC, Figueira WF, Ueland JS, Crowder LB.

Science. 2004 Sep 24;305(5692):1958-60. Epub 2004 Aug 26.

13.

The chemokine KC regulates HGF-stimulated epithelial cell morphogenesis.

Ueland JM, Gwira J, Liu ZX, Cantley LG.

Am J Physiol Renal Physiol. 2004 Mar;286(3):F581-9. Epub 2003 Nov 4.

Supplemental Content

Loading ...
Support Center